Brent Vaughan

Brent Vaughan is CEO of Cognito Therapeutics, a clinical-stage company leading the development of a new class of disease-modifying digital therapeutics to treat neurodegenerative disorders including Alzheimer’s disease. With more than 20 years of experience, he has a proven track record of success developing proprietary technologies and products across multiple domains, including digital therapeutics, medical devices, and pharmaceuticals.   

Prior to Cognito, Brent was Chief Executive Officer and Co-Founder at Cognoa, an AI-based digital therapeutics company, where he established the company as a leader in digital therapeutics and pediatric behavioral health. Under his leadership, Cognoa was awarded FDA Breakthrough Designation for the first two products for autism and successfully completed the clinical development of the lead product. He was also co-founder at WellnessFX, a leading digital health company.   

Brent has also held leadership positions in business development and product management in therapeutic and medical device companies including Saegis Pharmaceuticals, Nektar Therapeutics, and Roche.